Latest Insider Transactions at Crinetics Pharmaceuticals, Inc. (CRNX)
This section provides a real-time view of insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Crinetics Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Crinetics Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Caren Deardorf |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
Jun 07
2024
|
Wendall Wierenga |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+3.02%
|
-
|
|
Jun 07
2024
|
Camille L Bedrosian |
BUY
Grant, award, or other acquisition
|
Direct |
3,400
+26.56%
|
-
|
|
May 28
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.35%
|
$141,000
$47.49 P/Share
|
|
May 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.24%
|
$147,000
$49.43 P/Share
|
|
May 08
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
107,448
-29.44%
|
$5,264,952
$49.4 P/Share
|
|
May 08
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
107,448
+22.75%
|
$967,032
$9.28 P/Share
|
|
Apr 18
2024
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Direct |
350
-0.14%
|
-
|
|
Apr 15
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-34.1%
|
$632,500
$44.47 P/Share
|
|
Apr 15
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+25.43%
|
$230,000
$16.89 P/Share
|
|
Apr 15
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+7.2%
|
$20,000
$1.91 P/Share
|
|
Apr 04
2024
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
40,951
-14.69%
|
$2,006,599
$49.17 P/Share
|
|
Apr 04
2024
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,951
+12.81%
|
$368,559
$9.28 P/Share
|
|
Mar 28
2024
|
Stephanie Okey |
SELL
Open market or private sale
|
Direct |
17,500
-74.47%
|
$805,000
$46.38 P/Share
|
|
Mar 28
2024
|
Stephanie Okey |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+42.68%
|
$315,000
$18.29 P/Share
|
|
Mar 22
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
32,359
-19.81%
|
$1,423,796
$44.81 P/Share
|
|
Mar 22
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+26.1%
|
$690,000
$23.98 P/Share
|
|
Mar 20
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
15,089
-13.93%
|
$663,916
$44.29 P/Share
|
|
Mar 20
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+16.18%
|
$230,000
$16.89 P/Share
|
|
Mar 20
2024
|
Matthew K Fust |
SELL
Open market or private sale
|
Direct |
60,000
-44.42%
|
$2,640,000
$44.06 P/Share
|
|
Mar 20
2024
|
Matthew K Fust |
BUY
Exercise of conversion of derivative security
|
Direct |
60,000
+30.7%
|
$1,260,000
$21.25 P/Share
|
|
Mar 19
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
6,942
-5.9%
|
$291,564
$42.91 P/Share
|
|
Mar 18
2024
|
Jeff E. Knight Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,283
-7.23%
|
$162,754
$38.14 P/Share
|
|
Mar 18
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
411
-1.42%
|
$15,618
$38.14 P/Share
|
|
Mar 18
2024
|
Richard Scott Struthers President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,687
-5.06%
|
$482,106
$38.14 P/Share
|
|
Mar 18
2024
|
Marc Wilson CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,983
-3.28%
|
$151,354
$38.14 P/Share
|
|
Mar 18
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,655
-3.8%
|
$138,890
$38.14 P/Share
|
|
Mar 18
2024
|
James Hassard Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,741
-5.62%
|
$66,158
$38.14 P/Share
|
|
Mar 04
2024
|
James Hassard Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,000
+35.42%
|
-
|
|
Mar 04
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+44.31%
|
-
|
|
Mar 04
2024
|
Richard Scott Struthers President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+20.6%
|
-
|
|
Mar 04
2024
|
Marc Wilson CFO |
BUY
Grant, award, or other acquisition
|
Direct |
25,500
+17.34%
|
-
|
|
Mar 04
2024
|
Stephen F. Betz Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+19.28%
|
-
|
|
Mar 04
2024
|
Jeff E. Knight Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+27.97%
|
-
|
|
Feb 12
2024
|
Richard Scott Struthers President & CEO |
BUY
Bona fide gift
|
Indirect |
60,000
+15.38%
|
-
|
|
Feb 12
2024
|
Richard Scott Struthers President & CEO |
SELL
Bona fide gift
|
Indirect |
60,000
-9.51%
|
-
|
|
Jan 25
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.93%
|
$111,000
$37.26 P/Share
|
|
Jan 10
2024
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.78%
|
$111,000
$37.65 P/Share
|
|
Jan 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
14,375
-70.86%
|
$503,125
$35.0 P/Share
|
|
Jan 03
2024
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,375
+41.47%
|
$230,000
$16.89 P/Share
|
|
Jan 02
2024
|
Marc Wilson CFO |
SELL
Open market or private sale
|
Direct |
10,000
-9.43%
|
$350,000
$35.47 P/Share
|
|
Jan 02
2024
|
Marc Wilson CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.62%
|
$90,000
$9.28 P/Share
|
|
Dec 26
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.65%
|
$105,000
$35.89 P/Share
|
|
Dec 21
2023
|
Dana Pizzuti Chief Med and Dev Officer |
SELL
Open market or private sale
|
Direct |
9,583
-61.85%
|
$325,822
$34.57 P/Share
|
|
Dec 21
2023
|
Dana Pizzuti Chief Med and Dev Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,583
+38.21%
|
$153,328
$16.89 P/Share
|
|
Dec 11
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.52%
|
$96,000
$32.87 P/Share
|
|
Nov 27
2023
|
Stephen F. Betz Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,000
-3.4%
|
$93,000
$31.84 P/Share
|
|
Nov 09
2023
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+21.23%
|
$50,000
$1.91 P/Share
|
|
Nov 03
2023
|
Richard Scott Struthers President & CEO |
SELL
Open market or private sale
|
Direct |
199,082
-59.5%
|
$5,972,460
$30.56 P/Share
|
|
Nov 03
2023
|
Richard Scott Struthers President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
199,082
+37.3%
|
$1,791,738
$9.28 P/Share
|